Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Study Details
Study Description
Brief Summary
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
PRIMARY OBJECTIVE:
- To determine if bortezomib, daratumumab and hyaluronidase-fihj (daratumumab), lenalidomide and dexamethasone (Btz-DRd) consolidation followed by daratumumab and lenalidomide (DR) maintenance after standard induction therapy with daratumumab, lenalidomide and dexamethasone (DRd) results in superior overall survival compared to DRd consolidation followed by DR maintenance, in minimal residual disease (MRD) positive patients.
SECONDARY OBJECTIVES:
-
To determine if Btz-DRd consolidation followed by DR maintenance after standard induction therapy with DRd results in superior overall survival compared to DRd consolidation followed by DR maintenance in MRD negative patients.
-
To determine if Btz-DRd consolidation followed by DR maintenance after standard induction therapy with DRd results in superior progression-free survival compared to DRd consolidation followed by DR maintenance in both MRD positive and MRD negative patients.
-
To describe and compare the incidence of toxicities during consolidation between Btz-DRd and DRd arms.
-
To assess the improvement in MRD negative rate with consolidation among patients who are MRD positive after induction.
-
To assess the sustained MRD negative rate among patients who are MRD negative after induction.
PATIENT REPORTED OUTCOMES (PRO) OBJECTIVES:
- To quantify the extent to which the addition of bortezomib to DRd over consolidation treatment contributes to neuropathy and associated physical and functional impairments. (Primary PRO Objective) II. To evaluate the rate of resolution of neurotoxicity and associated physical and functional impairments following completion of consolidation therapy. (Secondary PRO Objective) III. To investigate the relationship between MRD status and patient reported health-related quality of life outcomes. (Exploratory PRO Objective) IV. To evaluate attributes of select patient reported treatment-emergent symptomatic adverse events (PRO- Common Terminology Criteria for Adverse Events [CTCAE]) longitudinally and compare responses with provider-reported adverse events. (Exploratory PRO Objective) V. To tabulate PRO compliance and completion rates. (Exploratory PRO Objective)
IMAGING OBJECTIVES:
- To evaluate the association between post-induction fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET)/computed tomography (CT) and patient outcomes (overall survival [OS] and progression-free survival [PFS]). (Primary Imaging Objective) II. To evaluate the association between baseline 18F-FDG PET/CT and patient outcomes (PFS and OS). (Secondary Imaging Objective) III. To compare overall survival with the addition of Bortezomib to consolidation DRd therapy among 18F-FDG PET/CT-positive and 18F-FDG PET/CT-negative subgroups. (Secondary Imaging Objective) IV. To evaluate the ability of baseline 18F-FDG PET/CT to predict post-induction depth of response as measured by MRD assessment. (Secondary Imaging Objective) V. To evaluate the ability of post-induction 18F-FDG PET/CT to predict MRD conversion post-consolidation. (Secondary Imaging Objective) VI. To utilize 18F-FDG PET/CT, standard risk factors and clinical data to identify distinct subgroups with differing patient outcomes (PFS and OS). (Exploratory Imaging Objective) VII. To compare the various qualitative 18F-FDG PET/CT criteria to determine which criteria yields superior risk stratification. (Exploratory Imaging Objective)
OUTLINE:
ARM A (INDUCTION): All patients receive standard induction therapy comprising the following:
daratumumab subcutaneously (SC) on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of cycles 7-9, lenalidomide orally (PO) daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.
After completion of standard induction therapy, patients are randomized to 1 of 2 arms.
ARM B:
CONSOLIDATION: Patients receive bortezomib SC on days 1, 8, and 15, daratumumab SC on day 1, lenalidomide PO daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.
MAINTENANCE: Patients receive lenalidomide PO daily on days 1-21 and daratumumab SC on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
ARM C:
CONSOLIDATION: Patients receive daratumumab SC on day 1, lenalidomide PO daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.
MAINTENANCE: Patients receive lenalidomide PO daily on days 1-21, and daratumumab SC on day
- Cycles repeats every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months if less than 2 years from study entry, every 6 months if 2-5 years from study entry, then annually for up to 15 years from study entry.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Arm A (daratumumab, lenalidomide, dexamethasone) INDUCTION: All patients receive standard induction therapy comprising the following: daratumumab subcutaneously (SC) on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of cycles 7-9, lenalidomide orally (PO) daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity. |
Biological: Daratumumab and Hyaluronidase-fihj
Given SC
Other Names:
Drug: Dexamethasone
Given PO
Other Names:
Drug: Lenalidomide
Given PO
Other Names:
Other: Quality-of-Life Assessment
Ancillary studies
Other Names:
|
| Experimental: Arm B (bortezomib, daratumumab, lenalidomide, dexamethasone) CONSOLIDATION: Patients receive bortezomib SC on days 1, 8, and 15, daratumumab SC on day 1, lenalidomide PO daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive lenalidomide PO daily on days 1-21 and daratumumab SC on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
Drug: Bortezomib
Given SC
Other Names:
Biological: Daratumumab and Hyaluronidase-fihj
Given SC
Other Names:
Drug: Dexamethasone
Given PO
Other Names:
Drug: Lenalidomide
Given PO
Other Names:
Other: Quality-of-Life Assessment
Ancillary studies
Other Names:
|
| Active Comparator: Arm C (daratumumab, lenalidomide, dexamethasone) CONSOLIDATION: Patients receive daratumumab SC on day 1, lenalidomide PO daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive lenalidomide PO daily on days 1-21, and daratumumab SC on day 1. Cycles repeats every 28 days in the absence of disease progression or unacceptable toxicity. |
Biological: Daratumumab and Hyaluronidase-fihj
Given SC
Other Names:
Drug: Dexamethasone
Given PO
Other Names:
Drug: Lenalidomide
Given PO
Other Names:
Other: Quality-of-Life Assessment
Ancillary studies
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Consolidation overall survival [Time from Step 2 randomization at the start of consolidation to death or to the date last known alive, assessed up to 15 years]
Will be estimated using the Kaplan-Meier (KM) method and compared using a stratified log-rank test. Stratified cox proportional hazards regression will produce treatment hazard ratio (bortezomib, daratumumab and hyaluronidase-fihj (daratumumab), lenalidomide and dexamethasone [Btz-DRd] then daratumumab, lenalidomide and dexamethasone [DRd] then daratumumab and lenalidomide [DR]).
Secondary Outcome Measures
- Consolidation progression-free survival [Time from Step 2 randomization at the start of consolidation until the earlier of progression or death due to any cause, assessed up to 15 years]
Patients alive without disease progression will be censored at date of last disease evaluation. Only deaths that occur within 3 months of the last disease evaluation are considered events.
- Incidence of adverse events [During induction, consolidation, and maintenance; a period of up to 42 months (9 months of induction, 9 months of consolidation, and up to 2 years of maintenance).]
- Incidence of grade 3 or higher non-hematologic adverse events [During induction, consolidation, and maintenance; a period of up to 42 months (9 months of induction, 9 months of consolidation, and up to 2 years of maintenance).]
- Incidence of grade 3 or higher adverse events [During induction, consolidation, and maintenance; a period of up to 42 months (9 months of induction, 9 months of consolidation, and up to 2 years of maintenance).]
- Best response [During induction, consolidation, and maintenance; a period of up to 42 months (9 months of induction, 9 months of consolidation, and up to 2 years of maintenance).]
- FACT-Ntx TOI recovery rate (Patient reported outcome [PRO]) [From end of induction through consolidation up to 1 year of maintenance, up to 21 weeks]
Defined as the proportion of patients with the FACT-Ntx TOI score returning to baseline level reached at consolidation randomization after experiencing a MID decrease while on up to 1 year of maintenance.
Other Outcome Measures
- Change in Functional Assessment of Cancer Therapy - Neurotoxicity Trial Outcome Index (FACT-Ntx TOI) score (Patient reported outcome) [From end of induction to after completion of 9 cycles of consolidation, a period of approximately 36 weeks (9 months)]
Calculated as the difference after completion of 9 cycles of consolidation therapy from end of induction. Scores can range from a minimum of 0 and a maximum of 44. A higher score on this assessment means a worse outcome.
- Levels and changes of FACT-General (G) (physical well-being [PWB] + functional well-being [FWB]) score (PRO) [From the end of induction through 1 year of maintenance, 21 weeks]
The FACT-G is a single outcome measure made up of the PWB and FWB components. Scores range from a minimum of 0 and a maximum of 56. For this assessment, a higher score means a better outcome.
- Presence, frequency, interference, amount and/or severity of select PRO- Common Terminology Criteria for Adverse Events (CTCAEs) (PRO) [Up to 15 years]
Presence, frequency, interference, amount and/or severity of select PRO-CTCAEs tabulated at each measurement.
- Comparison of selected PRO-CTCAEs with provider obtained assessment of same CTCAE items (PRO) [Up to 15 years]
- PRO compliance rate [Up to 15 years]
Defined as the proportion of patients who submit the given PRO instrument among those eligible at each time point which excludes those missing by design (due to death or disease progression, early treatment discontinuation).
- PRO completion rate [Up to 15 years]
Defined as the proportion of patients who complete given PRO instrument based on the instrument's scoring system among those eligible at each time point.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
STEP 0 - Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2 (PS 3 allowed if secondary to pain)
-
STEP 0 - Patient must have newly diagnosed multiple myeloma (MM) by International Myeloma Working Group (IMWG) criteria
-
STEP 0 - Patient must agree to register to the mandatory REVLIMID Risk Evaluation and Mitigation Strategy (RevREMS) program and be willing and able to comply with the requirements of RevREMS
-
STEP 0 - Patient must be able to undergo diagnostic bone marrow aspirate following preregistration.
-
NOTE: Bone marrow aspirate specimen must be submitted to Adaptive Biotechnologies for clonoSEQ Assay
-
NOTE: Adaptive Biotechnologies will release results to the diagnostic Portal from the Clonality (ID) test within fourteen (14) days of receipt and reconciliation of fresh bone marrow specimen to the submitting institution
-
STEP 1 - Patient must meet all eligibility criteria in STEP 0 with exception of allergy requirement
-
STEP 1 - Institution must have received the Clonality (ID) test results from Adaptive Biotechnologies and dominant sequences were identified
-
STEP 1 - Patient must have standard risk MM as defined by the Revised International Staging System (RISS) stage I or II
-
NOTE: R-ISS stage is based on serum beta2 microglobulin, albumin and lactate dehydrogenase (LDH) levels along with presence of chromosomal abnormalities (CA) detected by interphase fluorescent in situ hybridization (iFISH). Presence of del(17p), t(4;14), and/or t(14;16) is considered high risk and absence of these, including any other findings, are standard risk
-
R-ISS stage
-
Stage I: ISS stage I [beta2 macroglobulin < 3.5 mg/L, albumin > 3.5 g/dL] AND standard-risk CA AND normal LDH
-
Stage II: Not R-ISS stage I or III
-
Stage III: ISS stage III [beta2 macroglobulin > 5.5 mg/L] AND high-risk CA OR high LDH (> upper limit of normal) [patients with stage III are ineligible]
-
STEP 1 - Patient must have measurable or evaluable disease as defined by having one or more of the following, obtained within 28 days prior to registration:
-
= 1 g/dL monoclonal protein (M-protein) on serum protein electrophoresis
-
= 200 mg/24 hours of monoclonal protein on a 24-hour urine protein electrophoresis
-
Involved free light chain >= 10 mg/dL or >= 100 mg/L AND abnormal serum immunoglobulin kappa to lambda free light chain ratio (< 0.26 or > 1.65)
-
Monoclonal bone marrow plasmacytosis >= 30% (evaluable disease)
-
STEP 1 - Patients must have a serum protein electrophoresis (SPEP), urine protein electrophoresis (UPEP), and serum free light chain (FLC) assay performed within 28 days prior to registration. In addition, a bone marrow biopsy and/or aspirate is required within 28 days if bone marrow is being followed for response
-
NOTE: UPEP (on a 24-hour collection) is required, no substitute method is acceptable. Urine must be followed monthly if the baseline urine M-spike is >= 200 mg/24 hr. Please note that if both serum and urine M-components are present, both must be followed in order to evaluate response
-
NOTE: The serum free light chain test is required to be done if the patient does not have measurable disease in the serum or urine. Measurable disease in the serum is defined as having a serum M-spike >= 1 g/dL. Measurable disease in the urine is defined as having a urine M-spike >= 200 mg/24 hr
-
STEP 1 - Calculated creatinine clearance > 30 mL/min (obtained =< 14 days prior to Step 1 registration)
-
STEP 1 - Absolute neutrophil count (ANC) >= 1000/mm^3 (obtained =< 14 days prior to Step 1 registration)
-
STEP 1 - Untransfused platelet count >= 75,000/mm^3 (obtained =< 14 days prior to Step 1 registration)
-
STEP 1 - Hemoglobin >= 8.0 g/dL (obtained =< 14 days prior to Step 1 registration)
-
STEP 1 - Total bilirubin =< 1.5 x ULN (institutional upper limit of normal) (obtained =< 14 days prior to Step 1 registration)
-
STEP 1 - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN (obtained =< 14 days prior to Step 1 registration)
-
STEP 1 - Patient must have received no more than one cycle (28 days or less) of prior chemotherapy and no more than 160 mg of prior dexamethasone (or equivalent dose of prednisone) for treatment of symptomatic myeloma. Patient must not have been exposed to daratumumab for treatment of symptomatic myeloma. Prior radiation therapy to symptomatic lesions is allowed provided there are no residual toxicity related to radiation and blood counts meet the study requirements. Radiation treatment must be completed at least 14 days prior to Step 1 registration
-
STEP 1 - Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial
-
STEP 1 - For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
STEP 1 - Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
STEP 1 - Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
STEP 1 - Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better. Patients must not have evidence of current uncontrolled cardiovascular conditions, including hypertension, cardiac arrhythmias, congestive heart failure, unstable angina, or myocardial infarction within 6 months prior to Step 1 registration
-
STEP 1 - Patient may have a history of current or previous deep vein thrombosis (DVT) or pulmonary embolism (PE) but must be willing to take some form of anti-coagulation as prophylaxis if they are not currently on full-dose anticoagulation
-
STEP 1 - Patients with a history of chronic obstructive pulmonary disease (COPD) must have FEV1 testing done within 28 days prior to Step 1 registration and the forced expiratory volume in 1 second (FEV1) must be > 50% of predicted normal
-
STEP 2 - Institution must have received Tracking (MRD) test results from Adaptive Biotechnologies
-
STEP 2 - Patient must have completed the Step 1 Induction phase of this protocol without experiencing progression
-
STEP 2 - Patient must be registered to Step 2 within 8 weeks of completing Step 1 Induction Treatment, counting from last day of completion of last cycle
-
STEP 2 - Patient must have an ECOG performance status (PS) of 0-2 (PS 3 allowed if secondary to pain)
-
STEP 2 - Any adverse event(s) related to Step 1 Induction Treatment must have resolved to grade 2 or less
-
STEP 2 - Hemoglobin >= 8 g/dL (obtained within 14 days prior to Step 2 randomization)
-
STEP 2 - Platelet count >= 50,000/mm^3 (obtained within 14 days prior to Step 2 randomization)
-
STEP 2 - Absolute neutrophil count (ANC) >= 1000/mm^3 (obtained within 14 days prior to Step 2 randomization)
-
STEP 2 - Calculated creatinine clearance >= 30 mL/min (obtained within 14 days prior to Step 2 randomization)
-
STEP 2 - Total bilirubin =< 1.5 x ULN (Institutional upper limit of normal) (obtained within 14 days prior to Step 2 randomization)
-
STEP 2 - ALT and AST < 3 x ULN (obtained within 14 days prior to Step 2 randomization)
Exclusion Criteria:
-
STEP 0 - Patient must not have any known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies or human proteins, or their excipients (refer to respective package inserts or Investigator's Brochure), or known sensitivity to mammalian-derived products
-
STEP 1 - Women must not be pregnant or breast-feeding due to the potential harm and teratogenic effects to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All females of childbearing potential must have a blood test or urine study with a sensitivity of at least 25 mIU/mL within 10-14 days prior to Step 1 registration to rule out pregnancy and again within 24 hours prior to the first dose of lenalidomide. Females of childbearing potential must also agree to ongoing pregnancy testing while on protocol treatment. A female of childbearing potential is defined as any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:
-
Has achieved menarche at some point,
-
Has not undergone a hysterectomy or bilateral oophorectomy; or
-
Has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
STEP 1 - Women of childbearing potential must not expect to conceive children by using accepted and effective method(s) of contraception (for this protocol defined as the use of TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME for 1) at least 28 days before starting protocol treatment; 2) while participating in the study; 3) during dose interruptions; and 4) for at least 3 months days after the last dose of protocol treatment) OR by practicing true abstinence from sexual intercourse for the duration of their participation in the study (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception). Men must not expect to father children by practicing true abstinence from sexual intercourse for the duration of their participation in the study (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception) OR use a latex condom during sexual contact with a female of child bearing potential while participating in the study and for at least 3 months after the last dose of protocol treatment even if they have had a successful vasectomy. Men must also agree to abstain from donating sperm while on study treatment and for 3 months after the last dose of protocol treatment even if they have had a successful vasectomy. Both women and men must both agree to abstain from donating blood during study participation and for at least 28 days after the last dose of protocol treatment
-
STEP 1 - Patient must not have peripheral neuropathy >= grade 2 on clinical examination or grade 1 with pain at time of Step 1 registration
-
STEP 1 - Patient must not have any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol
-
STEP 1 - Patient must not have moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification
-
NOTE: Patients who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed to register
-
STEP 1 - Patient must not receive any other concurrent chemotherapy, or any ancillary therapy considered investigational while on this protocol
-
NOTE: Bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatment
-
STEP 2 - Patient must not have received any non-protocol therapy outside of the assigned Step 1 Induction treatment including stem cell transplant
-
STEP 2 - Women must not be pregnant or breast-feeding due to the potential harm and teratogenic effects to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All females of childbearing potential must have a blood test or urine study with a sensitivity of at least 25 mIU/mL within 10-14 days prior to Step 2 randomization to rule out pregnancy and again within 24 hours prior to the first dose of lenalidomide. Females of childbearing potential must also agree to ongoing pregnancy testing while on protocol treatment. A female of childbearing potential is defined as any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:
-
Has achieved menarche at some point,
-
Has not undergone a hysterectomy or bilateral oophorectomy; or
-
Has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
-
STEP 2 - Women of childbearing potential must not expect to conceive children by using accepted and effective method(s) of contraception (for this protocol defined as the use of TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME for 1) at least 28 days before starting protocol treatment; 2) while participating in the study; 3) during dose interruptions; and 4) for at least 3 months days after the last dose of protocol treatment) OR by practicing true abstinence from sexual intercourse for the duration of their participation in the study (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception).
Men must not expect to father children by practicing true abstinence from sexual intercourse for the duration of their participation in the study (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception) OR use a latex condom during sexual contact with a female of child bearing potential while participating in the study and for at least 3 months after the last dose of protocol treatment even if they have had a successful vasectomy. Men must also agree to abstain from donating sperm while on study treatment and for 3 months after the last dose of protocol treatment even if they have had a successful vasectomy. Both women and men must both agree to abstain from donating blood during study participation and for at least 28 days after the last dose of protocol treatment
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Anchorage Associates in Radiation Medicine | Anchorage | Alaska | United States | 98508 |
| 2 | Anchorage Radiation Therapy Center | Anchorage | Alaska | United States | 99504 |
| 3 | Alaska Breast Care and Surgery LLC | Anchorage | Alaska | United States | 99508 |
| 4 | Alaska Oncology and Hematology LLC | Anchorage | Alaska | United States | 99508 |
| 5 | Alaska Women's Cancer Care | Anchorage | Alaska | United States | 99508 |
| 6 | Anchorage Oncology Centre | Anchorage | Alaska | United States | 99508 |
| 7 | Katmai Oncology Group | Anchorage | Alaska | United States | 99508 |
| 8 | Providence Alaska Medical Center | Anchorage | Alaska | United States | 99508 |
| 9 | Cancer Center at Saint Joseph's | Phoenix | Arizona | United States | 85004 |
| 10 | University of Arizona Cancer Center-Orange Grove Campus | Tucson | Arizona | United States | 85704 |
| 11 | Banner University Medical Center - Tucson | Tucson | Arizona | United States | 85719 |
| 12 | University of Arizona Cancer Center-North Campus | Tucson | Arizona | United States | 85719 |
| 13 | Mercy Hospital Fort Smith | Fort Smith | Arkansas | United States | 72903 |
| 14 | CHI Saint Vincent Cancer Center Hot Springs | Hot Springs | Arkansas | United States | 71913 |
| 15 | Mission Hope Medical Oncology - Arroyo Grande | Arroyo Grande | California | United States | 93420 |
| 16 | Providence Saint Joseph Medical Center/Disney Family Cancer Center | Burbank | California | United States | 91505 |
| 17 | Pacific Central Coast Health Center-San Luis Obispo | San Luis Obispo | California | United States | 93401 |
| 18 | Mission Hope Medical Oncology - Santa Maria | Santa Maria | California | United States | 93444 |
| 19 | Penrose-Saint Francis Healthcare | Colorado Springs | Colorado | United States | 80907 |
| 20 | Rocky Mountain Cancer Centers-Penrose | Colorado Springs | Colorado | United States | 80907 |
| 21 | Saint Francis Cancer Center | Colorado Springs | Colorado | United States | 80923 |
| 22 | Porter Adventist Hospital | Denver | Colorado | United States | 80210 |
| 23 | Mercy Medical Center | Durango | Colorado | United States | 81301 |
| 24 | Southwest Oncology PC | Durango | Colorado | United States | 81301 |
| 25 | Saint Anthony Hospital | Lakewood | Colorado | United States | 80228 |
| 26 | Littleton Adventist Hospital | Littleton | Colorado | United States | 80122 |
| 27 | Longmont United Hospital | Longmont | Colorado | United States | 80501 |
| 28 | Rocky Mountain Cancer Centers-Longmont | Longmont | Colorado | United States | 80501 |
| 29 | Parker Adventist Hospital | Parker | Colorado | United States | 80138 |
| 30 | Saint Mary Corwin Medical Center | Pueblo | Colorado | United States | 81004 |
| 31 | Smilow Cancer Hospital-Derby Care Center | Derby | Connecticut | United States | 06418 |
| 32 | Smilow Cancer Hospital Care Center-Fairfield | Fairfield | Connecticut | United States | 06824 |
| 33 | Smilow Cancer Hospital Care Center at Glastonbury | Glastonbury | Connecticut | United States | 06033 |
| 34 | Smilow Cancer Hospital Care Center at Greenwich | Greenwich | Connecticut | United States | 06830 |
| 35 | Smilow Cancer Hospital Care Center - Guiford | Guilford | Connecticut | United States | 06437 |
| 36 | Smilow Cancer Hospital Care Center at Saint Francis | Hartford | Connecticut | United States | 06105 |
| 37 | Smilow Cancer Center/Yale-New Haven Hospital | New Haven | Connecticut | United States | 06510 |
| 38 | Yale University | New Haven | Connecticut | United States | 06520 |
| 39 | Yale-New Haven Hospital North Haven Medical Center | North Haven | Connecticut | United States | 06473 |
| 40 | Smilow Cancer Hospital-Orange Care Center | Orange | Connecticut | United States | 06477 |
| 41 | Smilow Cancer Hospital-Torrington Care Center | Torrington | Connecticut | United States | 06790 |
| 42 | Smilow Cancer Hospital Care Center-Trumbull | Trumbull | Connecticut | United States | 06611 |
| 43 | Smilow Cancer Hospital-Waterbury Care Center | Waterbury | Connecticut | United States | 06708 |
| 44 | Smilow Cancer Hospital Care Center - Waterford | Waterford | Connecticut | United States | 06385 |
| 45 | Beebe South Coastal Health Campus | Frankford | Delaware | United States | 19945 |
| 46 | Beebe Medical Center | Lewes | Delaware | United States | 19958 |
| 47 | Delaware Clinical and Laboratory Physicians PA | Newark | Delaware | United States | 19713 |
| 48 | Helen F Graham Cancer Center | Newark | Delaware | United States | 19713 |
| 49 | Medical Oncology Hematology Consultants PA | Newark | Delaware | United States | 19713 |
| 50 | Christiana Care Health System-Christiana Hospital | Newark | Delaware | United States | 19718 |
| 51 | Beebe Health Campus | Rehoboth Beach | Delaware | United States | 19971 |
| 52 | TidalHealth Nanticoke / Allen Cancer Center | Seaford | Delaware | United States | 19973 |
| 53 | Christiana Care Health System-Wilmington Hospital | Wilmington | Delaware | United States | 19801 |
| 54 | Holy Cross Hospital | Fort Lauderdale | Florida | United States | 33308 |
| 55 | Sacred Heart Hospital | Pensacola | Florida | United States | 32504 |
| 56 | Saint Alphonsus Cancer Care Center-Boise | Boise | Idaho | United States | 83706 |
| 57 | Saint Luke's Cancer Institute - Boise | Boise | Idaho | United States | 83712 |
| 58 | Saint Alphonsus Cancer Care Center-Caldwell | Caldwell | Idaho | United States | 83605 |
| 59 | Kootenai Health - Coeur d'Alene | Coeur d'Alene | Idaho | United States | 83814 |
| 60 | Walter Knox Memorial Hospital | Emmett | Idaho | United States | 83617 |
| 61 | Saint Luke's Cancer Institute - Fruitland | Fruitland | Idaho | United States | 83619 |
| 62 | Idaho Urologic Institute-Meridian | Meridian | Idaho | United States | 83642 |
| 63 | Saint Luke's Cancer Institute - Meridian | Meridian | Idaho | United States | 83642 |
| 64 | Saint Alphonsus Medical Center-Nampa | Nampa | Idaho | United States | 83686 |
| 65 | Saint Luke's Cancer Institute - Nampa | Nampa | Idaho | United States | 83686 |
| 66 | Kootenai Clinic Cancer Services - Post Falls | Post Falls | Idaho | United States | 83854 |
| 67 | Kootenai Cancer Clinic | Sandpoint | Idaho | United States | 83864 |
| 68 | Saint Luke's Cancer Institute - Twin Falls | Twin Falls | Idaho | United States | 83301 |
| 69 | Saint Anthony's Health | Alton | Illinois | United States | 62002 |
| 70 | Rush - Copley Medical Center | Aurora | Illinois | United States | 60504 |
| 71 | Illinois CancerCare-Bloomington | Bloomington | Illinois | United States | 61704 |
| 72 | Loyola Center for Health at Burr Ridge | Burr Ridge | Illinois | United States | 60527 |
| 73 | Illinois CancerCare-Canton | Canton | Illinois | United States | 61520 |
| 74 | Memorial Hospital of Carbondale | Carbondale | Illinois | United States | 62902 |
| 75 | SIH Cancer Institute | Carterville | Illinois | United States | 62918 |
| 76 | Illinois CancerCare-Carthage | Carthage | Illinois | United States | 62321 |
| 77 | Centralia Oncology Clinic | Centralia | Illinois | United States | 62801 |
| 78 | University of Illinois | Chicago | Illinois | United States | 60612 |
| 79 | Carle on Vermilion | Danville | Illinois | United States | 61832 |
| 80 | Cancer Care Specialists of Illinois - Decatur | Decatur | Illinois | United States | 62526 |
| 81 | Decatur Memorial Hospital | Decatur | Illinois | United States | 62526 |
| 82 | Northwestern Medicine Cancer Center Kishwaukee | DeKalb | Illinois | United States | 60115 |
| 83 | Illinois CancerCare-Dixon | Dixon | Illinois | United States | 61021 |
| 84 | Carle Physician Group-Effingham | Effingham | Illinois | United States | 62401 |
| 85 | Crossroads Cancer Center | Effingham | Illinois | United States | 62401 |
| 86 | Illinois CancerCare-Eureka | Eureka | Illinois | United States | 61530 |
| 87 | Illinois CancerCare-Galesburg | Galesburg | Illinois | United States | 61401 |
| 88 | Western Illinois Cancer Treatment Center | Galesburg | Illinois | United States | 61401 |
| 89 | Northwestern Medicine Cancer Center Delnor | Geneva | Illinois | United States | 60134 |
| 90 | Loyola Medicine Homer Glen | Homer Glen | Illinois | United States | 60491 |
| 91 | Illinois CancerCare-Kewanee Clinic | Kewanee | Illinois | United States | 61443 |
| 92 | Illinois CancerCare-Macomb | Macomb | Illinois | United States | 61455 |
| 93 | Carle Physician Group-Mattoon/Charleston | Mattoon | Illinois | United States | 61938 |
| 94 | Loyola University Medical Center | Maywood | Illinois | United States | 60153 |
| 95 | Marjorie Weinberg Cancer Center at Loyola-Gottlieb | Melrose Park | Illinois | United States | 60160 |
| 96 | Good Samaritan Regional Health Center | Mount Vernon | Illinois | United States | 62864 |
| 97 | Cancer Care Center of O'Fallon | O'Fallon | Illinois | United States | 62269 |
| 98 | Illinois CancerCare-Ottawa Clinic | Ottawa | Illinois | United States | 61350 |
| 99 | Illinois CancerCare-Pekin | Pekin | Illinois | United States | 61554 |
| 100 | Illinois CancerCare-Peoria | Peoria | Illinois | United States | 61615 |
| 101 | Methodist Medical Center of Illinois | Peoria | Illinois | United States | 61636 |
| 102 | Illinois CancerCare-Peru | Peru | Illinois | United States | 61354 |
| 103 | Valley Radiation Oncology | Peru | Illinois | United States | 61354 |
| 104 | Illinois CancerCare-Princeton | Princeton | Illinois | United States | 61356 |
| 105 | Southern Illinois University School of Medicine | Springfield | Illinois | United States | 62702 |
| 106 | Springfield Clinic | Springfield | Illinois | United States | 62702 |
| 107 | Memorial Medical Center | Springfield | Illinois | United States | 62781 |
| 108 | Carle Cancer Center | Urbana | Illinois | United States | 61801 |
| 109 | The Carle Foundation Hospital | Urbana | Illinois | United States | 61801 |
| 110 | Northwestern Medicine Cancer Center Warrenville | Warrenville | Illinois | United States | 60555 |
| 111 | Illinois CancerCare - Washington | Washington | Illinois | United States | 61571 |
| 112 | Rush-Copley Healthcare Center | Yorkville | Illinois | United States | 60560 |
| 113 | IU Health North Hospital | Carmel | Indiana | United States | 46032 |
| 114 | Indiana University/Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | United States | 46202 |
| 115 | IU Health Methodist Hospital | Indianapolis | Indiana | United States | 46202 |
| 116 | Reid Health | Richmond | Indiana | United States | 47374 |
| 117 | Mary Greeley Medical Center | Ames | Iowa | United States | 50010 |
| 118 | McFarland Clinic PC - Ames | Ames | Iowa | United States | 50010 |
| 119 | McFarland Clinic PC-Boone | Boone | Iowa | United States | 50036 |
| 120 | Saint Anthony Regional Hospital | Carroll | Iowa | United States | 51401 |
| 121 | Mercy Hospital | Cedar Rapids | Iowa | United States | 52403 |
| 122 | Oncology Associates at Mercy Medical Center | Cedar Rapids | Iowa | United States | 52403 |
| 123 | Medical Oncology and Hematology Associates-West Des Moines | Clive | Iowa | United States | 50325 |
| 124 | Mercy Cancer Center-West Lakes | Clive | Iowa | United States | 50325 |
| 125 | Alegent Health Mercy Hospital | Council Bluffs | Iowa | United States | 51503 |
| 126 | Greater Regional Medical Center | Creston | Iowa | United States | 50801 |
| 127 | Iowa Methodist Medical Center | Des Moines | Iowa | United States | 50309 |
| 128 | Medical Oncology and Hematology Associates-Des Moines | Des Moines | Iowa | United States | 50309 |
| 129 | Broadlawns Medical Center | Des Moines | Iowa | United States | 50314 |
| 130 | Medical Oncology and Hematology Associates-Laurel | Des Moines | Iowa | United States | 50314 |
| 131 | Mercy Medical Center - Des Moines | Des Moines | Iowa | United States | 50314 |
| 132 | Iowa Lutheran Hospital | Des Moines | Iowa | United States | 50316 |
| 133 | McFarland Clinic PC-Trinity Cancer Center | Fort Dodge | Iowa | United States | 50501 |
| 134 | Trinity Regional Medical Center | Fort Dodge | Iowa | United States | 50501 |
| 135 | McFarland Clinic PC-Jefferson | Jefferson | Iowa | United States | 50129 |
| 136 | McFarland Clinic PC-Marshalltown | Marshalltown | Iowa | United States | 50158 |
| 137 | Methodist West Hospital | West Des Moines | Iowa | United States | 50266-7700 |
| 138 | Mercy Medical Center-West Lakes | West Des Moines | Iowa | United States | 50266 |
| 139 | Central Care Cancer Center - Garden City | Garden City | Kansas | United States | 67846 |
| 140 | Central Care Cancer Center - Great Bend | Great Bend | Kansas | United States | 67530 |
| 141 | Flaget Memorial Hospital | Bardstown | Kentucky | United States | 40004 |
| 142 | Commonwealth Cancer Center-Corbin | Corbin | Kentucky | United States | 40701 |
| 143 | Saint Joseph Radiation Oncology Resource Center | Lexington | Kentucky | United States | 40504 |
| 144 | Saint Joseph Hospital East | Lexington | Kentucky | United States | 40509 |
| 145 | Saint Joseph London | London | Kentucky | United States | 40741 |
| 146 | Jewish Hospital | Louisville | Kentucky | United States | 40202 |
| 147 | Saints Mary and Elizabeth Hospital | Louisville | Kentucky | United States | 40215 |
| 148 | Jewish Hospital Medical Center Northeast | Louisville | Kentucky | United States | 40245 |
| 149 | Jewish Hospital Medical Center South | Shepherdsville | Kentucky | United States | 40165 |
| 150 | Ochsner LSU Health Monroe Medical Center | Monroe | Louisiana | United States | 71202 |
| 151 | LSU Health Sciences Center at Shreveport | Shreveport | Louisiana | United States | 71103 |
| 152 | Frederick Memorial Hospital | Frederick | Maryland | United States | 21701 |
| 153 | FMH James M Stockman Cancer Institute | Frederick | Maryland | United States | 21702 |
| 154 | Tufts Medical Center | Boston | Massachusetts | United States | 02111 |
| 155 | Hickman Cancer Center | Adrian | Michigan | United States | 49221 |
| 156 | Saint Joseph Mercy Hospital | Ann Arbor | Michigan | United States | 48106 |
| 157 | Bronson Battle Creek | Battle Creek | Michigan | United States | 49017 |
| 158 | IHA Hematology Oncology Consultants-Brighton | Brighton | Michigan | United States | 48114 |
| 159 | Saint Joseph Mercy Brighton | Brighton | Michigan | United States | 48114 |
| 160 | IHA Hematology Oncology Consultants-Canton | Canton | Michigan | United States | 48188 |
| 161 | Saint Joseph Mercy Canton | Canton | Michigan | United States | 48188 |
| 162 | Caro Cancer Center | Caro | Michigan | United States | 48723 |
| 163 | IHA Hematology Oncology Consultants-Chelsea | Chelsea | Michigan | United States | 48118 |
| 164 | Saint Joseph Mercy Chelsea | Chelsea | Michigan | United States | 48118 |
| 165 | Hematology Oncology Consultants-Clarkston | Clarkston | Michigan | United States | 48346 |
| 166 | Newland Medical Associates-Clarkston | Clarkston | Michigan | United States | 48346 |
| 167 | Ascension Saint John Hospital | Detroit | Michigan | United States | 48236 |
| 168 | Great Lakes Cancer Management Specialists-Doctors Park | East China Township | Michigan | United States | 48054 |
| 169 | Genesee Cancer and Blood Disease Treatment Center | Flint | Michigan | United States | 48503 |
| 170 | Genesee Hematology Oncology PC | Flint | Michigan | United States | 48503 |
| 171 | Genesys Hurley Cancer Institute | Flint | Michigan | United States | 48503 |
| 172 | Hurley Medical Center | Flint | Michigan | United States | 48503 |
| 173 | Helen DeVos Children's Hospital at Spectrum Health | Grand Rapids | Michigan | United States | 49503 |
| 174 | Mercy Health Saint Mary's | Grand Rapids | Michigan | United States | 49503 |
| 175 | Spectrum Health at Butterworth Campus | Grand Rapids | Michigan | United States | 49503 |
| 176 | Academic Hematology Oncology Specialists | Grosse Pointe Woods | Michigan | United States | 48236 |
| 177 | Great Lakes Cancer Management Specialists-Van Elslander Cancer Center | Grosse Pointe Woods | Michigan | United States | 48236 |
| 178 | Michigan Breast Specialists-Grosse Pointe Woods | Grosse Pointe Woods | Michigan | United States | 48236 |
| 179 | Bronson Methodist Hospital | Kalamazoo | Michigan | United States | 49007 |
| 180 | West Michigan Cancer Center | Kalamazoo | Michigan | United States | 49007 |
| 181 | Ascension Borgess Cancer Center | Kalamazoo | Michigan | United States | 49009 |
| 182 | Borgess Medical Center | Kalamazoo | Michigan | United States | 49048 |
| 183 | Sparrow Hospital | Lansing | Michigan | United States | 48912 |
| 184 | Hope Cancer Clinic | Livonia | Michigan | United States | 48154 |
| 185 | Saint Mary Mercy Hospital | Livonia | Michigan | United States | 48154 |
| 186 | Great Lakes Cancer Management Specialists-Macomb Medical Campus | Macomb | Michigan | United States | 48044 |
| 187 | Michigan Breast Specialists-Macomb Township | Macomb | Michigan | United States | 48044 |
| 188 | Saint Mary's Oncology/Hematology Associates of Marlette | Marlette | Michigan | United States | 48453 |
| 189 | Toledo Clinic Cancer Centers-Monroe | Monroe | Michigan | United States | 48162 |
| 190 | Mercy Health Mercy Campus | Muskegon | Michigan | United States | 49444 |
| 191 | Lakeland Hospital Niles | Niles | Michigan | United States | 49120 |
| 192 | Cancer and Hematology Centers of Western Michigan - Norton Shores | Norton Shores | Michigan | United States | 49444 |
| 193 | Ascension Providence Hospitals - Novi | Novi | Michigan | United States | 48374 |
| 194 | 21st Century Oncology-Pontiac | Pontiac | Michigan | United States | 48341 |
| 195 | Hope Cancer Center | Pontiac | Michigan | United States | 48341 |
| 196 | Newland Medical Associates-Pontiac | Pontiac | Michigan | United States | 48341 |
| 197 | Saint Joseph Mercy Oakland | Pontiac | Michigan | United States | 48341 |
| 198 | Spectrum Health Reed City Hospital | Reed City | Michigan | United States | 49677 |
| 199 | Great Lakes Cancer Management Specialists-Rochester Hills | Rochester Hills | Michigan | United States | 48309 |
| 200 | Ascension Saint Mary's Hospital | Saginaw | Michigan | United States | 48601 |
| 201 | Oncology Hematology Associates of Saginaw Valley PC | Saginaw | Michigan | United States | 48604 |
| 202 | Lakeland Medical Center Saint Joseph | Saint Joseph | Michigan | United States | 49085 |
| 203 | Marie Yeager Cancer Center | Saint Joseph | Michigan | United States | 49085 |
| 204 | Ascension Providence Hospitals - Southfield | Southfield | Michigan | United States | 48075 |
| 205 | Bhadresh Nayak MD PC-Sterling Heights | Sterling Heights | Michigan | United States | 48312 |
| 206 | Ascension Saint Joseph Hospital | Tawas City | Michigan | United States | 48764 |
| 207 | Munson Medical Center | Traverse City | Michigan | United States | 49684 |
| 208 | Advanced Breast Care Center PLLC | Warren | Michigan | United States | 48088 |
| 209 | Great Lakes Cancer Management Specialists-Macomb Professional Building | Warren | Michigan | United States | 48093 |
| 210 | Macomb Hematology Oncology PC | Warren | Michigan | United States | 48093 |
| 211 | Michigan Breast Specialists-Warren | Warren | Michigan | United States | 48093 |
| 212 | Saint John Macomb-Oakland Hospital | Warren | Michigan | United States | 48093 |
| 213 | Saint Mary's Oncology/Hematology Associates of West Branch | West Branch | Michigan | United States | 48661 |
| 214 | Metro Health Hospital | Wyoming | Michigan | United States | 49519 |
| 215 | Huron Gastroenterology PC | Ypsilanti | Michigan | United States | 48106 |
| 216 | IHA Hematology Oncology Consultants-Ann Arbor | Ypsilanti | Michigan | United States | 48197 |
| 217 | Sanford Joe Lueken Cancer Center | Bemidji | Minnesota | United States | 56601 |
| 218 | Fairview Ridges Hospital | Burnsville | Minnesota | United States | 55337 |
| 219 | Minnesota Oncology - Burnsville | Burnsville | Minnesota | United States | 55337 |
| 220 | Cambridge Medical Center | Cambridge | Minnesota | United States | 55008 |
| 221 | Mercy Hospital | Coon Rapids | Minnesota | United States | 55433 |
| 222 | Fairview Southdale Hospital | Edina | Minnesota | United States | 55435 |
| 223 | Unity Hospital | Fridley | Minnesota | United States | 55432 |
| 224 | Fairview Clinics and Surgery Center Maple Grove | Maple Grove | Minnesota | United States | 55369 |
| 225 | Minnesota Oncology Hematology PA-Maplewood | Maplewood | Minnesota | United States | 55109 |
| 226 | Saint John's Hospital - Healtheast | Maplewood | Minnesota | United States | 55109 |
| 227 | Abbott-Northwestern Hospital | Minneapolis | Minnesota | United States | 55407 |
| 228 | Hennepin County Medical Center | Minneapolis | Minnesota | United States | 55415 |
| 229 | Health Partners Inc | Minneapolis | Minnesota | United States | 55454 |
| 230 | Monticello Cancer Center | Monticello | Minnesota | United States | 55362 |
| 231 | New Ulm Medical Center | New Ulm | Minnesota | United States | 56073 |
| 232 | Fairview Northland Medical Center | Princeton | Minnesota | United States | 55371 |
| 233 | North Memorial Medical Health Center | Robbinsdale | Minnesota | United States | 55422 |
| 234 | Mayo Clinic in Rochester | Rochester | Minnesota | United States | 55905 |
| 235 | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park | Minnesota | United States | 55416 |
| 236 | Regions Hospital | Saint Paul | Minnesota | United States | 55101 |
| 237 | United Hospital | Saint Paul | Minnesota | United States | 55102 |
| 238 | Saint Francis Regional Medical Center | Shakopee | Minnesota | United States | 55379 |
| 239 | Lakeview Hospital | Stillwater | Minnesota | United States | 55082 |
| 240 | Sanford Thief River Falls Medical Center | Thief River Falls | Minnesota | United States | 56701 |
| 241 | Ridgeview Medical Center | Waconia | Minnesota | United States | 55387 |
| 242 | Rice Memorial Hospital | Willmar | Minnesota | United States | 56201 |
| 243 | Minnesota Oncology Hematology PA-Woodbury | Woodbury | Minnesota | United States | 55125 |
| 244 | Fairview Lakes Medical Center | Wyoming | Minnesota | United States | 55092 |
| 245 | Saint Louis Cancer and Breast Institute-Ballwin | Ballwin | Missouri | United States | 63011 |
| 246 | Central Care Cancer Center - Bolivar | Bolivar | Missouri | United States | 65613 |
| 247 | Cox Cancer Center Branson | Branson | Missouri | United States | 65616 |
| 248 | Saint Francis Medical Center | Cape Girardeau | Missouri | United States | 63703 |
| 249 | Southeast Cancer Center | Cape Girardeau | Missouri | United States | 63703 |
| 250 | Parkland Health Center - Farmington | Farmington | Missouri | United States | 63640 |
| 251 | Capital Region Southwest Campus | Jefferson City | Missouri | United States | 65109 |
| 252 | Freeman Health System | Joplin | Missouri | United States | 64804 |
| 253 | Mercy Hospital Joplin | Joplin | Missouri | United States | 64804 |
| 254 | Delbert Day Cancer Institute at PCRMC | Rolla | Missouri | United States | 65401 |
| 255 | Mercy Clinic-Rolla-Cancer and Hematology | Rolla | Missouri | United States | 65401 |
| 256 | Heartland Regional Medical Center | Saint Joseph | Missouri | United States | 64506 |
| 257 | Saint Louis Cancer and Breast Institute-South City | Saint Louis | Missouri | United States | 63109 |
| 258 | Mercy Hospital South | Saint Louis | Missouri | United States | 63128 |
| 259 | Missouri Baptist Medical Center | Saint Louis | Missouri | United States | 63131 |
| 260 | Mercy Hospital Saint Louis | Saint Louis | Missouri | United States | 63141 |
| 261 | Sainte Genevieve County Memorial Hospital | Sainte Genevieve | Missouri | United States | 63670 |
| 262 | Mercy Hospital Springfield | Springfield | Missouri | United States | 65804 |
| 263 | CoxHealth South Hospital | Springfield | Missouri | United States | 65807 |
| 264 | Missouri Baptist Sullivan Hospital | Sullivan | Missouri | United States | 63080 |
| 265 | Missouri Baptist Outpatient Center-Sunset Hills | Sunset Hills | Missouri | United States | 63127 |
| 266 | Mercy Hospital Washington | Washington | Missouri | United States | 63090 |
| 267 | Community Hospital of Anaconda | Anaconda | Montana | United States | 59711 |
| 268 | Billings Clinic Cancer Center | Billings | Montana | United States | 59101 |
| 269 | Bozeman Deaconess Hospital | Bozeman | Montana | United States | 59715 |
| 270 | Benefis Healthcare- Sletten Cancer Institute | Great Falls | Montana | United States | 59405 |
| 271 | Great Falls Clinic | Great Falls | Montana | United States | 59405 |
| 272 | Kalispell Regional Medical Center | Kalispell | Montana | United States | 59901 |
| 273 | Saint Patrick Hospital - Community Hospital | Missoula | Montana | United States | 59802 |
| 274 | Community Medical Hospital | Missoula | Montana | United States | 59804 |
| 275 | CHI Health Saint Francis | Grand Island | Nebraska | United States | 68803 |
| 276 | CHI Health Good Samaritan | Kearney | Nebraska | United States | 68847 |
| 277 | Saint Elizabeth Regional Medical Center | Lincoln | Nebraska | United States | 68510 |
| 278 | Alegent Health Immanuel Medical Center | Omaha | Nebraska | United States | 68122 |
| 279 | Alegent Health Bergan Mercy Medical Center | Omaha | Nebraska | United States | 68124 |
| 280 | Alegent Health Lakeside Hospital | Omaha | Nebraska | United States | 68130 |
| 281 | Creighton University Medical Center | Omaha | Nebraska | United States | 68131 |
| 282 | Midlands Community Hospital | Papillion | Nebraska | United States | 68046 |
| 283 | University of New Mexico Cancer Center | Albuquerque | New Mexico | United States | 87102 |
| 284 | Glens Falls Hospital | Glens Falls | New York | United States | 12801 |
| 285 | Stony Brook University Medical Center | Stony Brook | New York | United States | 11794 |
| 286 | Good Samaritan Hospital Medical Center | West Islip | New York | United States | 11795 |
| 287 | Southeastern Medical Oncology Center-Clinton | Clinton | North Carolina | United States | 28328 |
| 288 | Southeastern Medical Oncology Center-Goldsboro | Goldsboro | North Carolina | United States | 27534 |
| 289 | Southeastern Medical Oncology Center-Jacksonville | Jacksonville | North Carolina | United States | 28546 |
| 290 | Vidant Oncology-Kenansville | Kenansville | North Carolina | United States | 28349 |
| 291 | Vidant Oncology-Kinston | Kinston | North Carolina | United States | 28501 |
| 292 | Vidant Oncology-Richlands | Richlands | North Carolina | United States | 28574 |
| 293 | Sanford Bismarck Medical Center | Bismarck | North Dakota | United States | 58501 |
| 294 | Sanford South University Medical Center | Fargo | North Dakota | United States | 58103 |
| 295 | Southpointe-Sanford Medical Center Fargo | Fargo | North Dakota | United States | 58103 |
| 296 | Sanford Medical Center Fargo | Fargo | North Dakota | United States | 58104 |
| 297 | Sanford Broadway Medical Center | Fargo | North Dakota | United States | 58122 |
| 298 | Sanford Roger Maris Cancer Center | Fargo | North Dakota | United States | 58122 |
| 299 | UHHS-Chagrin Highlands Medical Center | Beachwood | Ohio | United States | 44122 |
| 300 | Indu and Raj Soin Medical Center | Beavercreek | Ohio | United States | 45431 |
| 301 | Strecker Cancer Center-Belpre | Belpre | Ohio | United States | 45714 |
| 302 | Saint Elizabeth Boardman Hospital | Boardman | Ohio | United States | 44512 |
| 303 | Dayton Physicians LLC-Miami Valley South | Centerville | Ohio | United States | 45459 |
| 304 | Miami Valley Hospital South | Centerville | Ohio | United States | 45459 |
| 305 | Geauga Hospital | Chardon | Ohio | United States | 44024 |
| 306 | Adena Regional Medical Center | Chillicothe | Ohio | United States | 45601 |
| 307 | University of Cincinnati Cancer Center-UC Medical Center | Cincinnati | Ohio | United States | 45219 |
| 308 | Good Samaritan Hospital - Cincinnati | Cincinnati | Ohio | United States | 45220 |
| 309 | Oncology Hematology Care Inc-Kenwood | Cincinnati | Ohio | United States | 45236 |
| 310 | Bethesda North Hospital | Cincinnati | Ohio | United States | 45242 |
| 311 | TriHealth Cancer Institute-Westside | Cincinnati | Ohio | United States | 45247 |
| 312 | TriHealth Cancer Institute-Anderson | Cincinnati | Ohio | United States | 45255 |
| 313 | Case Western Reserve University | Cleveland | Ohio | United States | 44106 |
| 314 | Mount Carmel East Hospital | Columbus | Ohio | United States | 43213 |
| 315 | Columbus Oncology and Hematology Associates Inc | Columbus | Ohio | United States | 43214 |
| 316 | Riverside Methodist Hospital | Columbus | Ohio | United States | 43214 |
| 317 | Grant Medical Center | Columbus | Ohio | United States | 43215 |
| 318 | The Mark H Zangmeister Center | Columbus | Ohio | United States | 43219 |
| 319 | Mount Carmel Health Center West | Columbus | Ohio | United States | 43222 |
| 320 | Doctors Hospital | Columbus | Ohio | United States | 43228 |
| 321 | Miami Valley Hospital | Dayton | Ohio | United States | 45409 |
| 322 | Dayton Physician LLC-Miami Valley Hospital North | Dayton | Ohio | United States | 45415 |
| 323 | Miami Valley Hospital North | Dayton | Ohio | United States | 45415 |
| 324 | Delaware Health Center-Grady Cancer Center | Delaware | Ohio | United States | 43015 |
| 325 | Grady Memorial Hospital | Delaware | Ohio | United States | 43015 |
| 326 | Dublin Methodist Hospital | Dublin | Ohio | United States | 43016 |
| 327 | Armes Family Cancer Center | Findlay | Ohio | United States | 45840 |
| 328 | Blanchard Valley Hospital | Findlay | Ohio | United States | 45840 |
| 329 | Orion Cancer Care | Findlay | Ohio | United States | 45840 |
| 330 | Atrium Medical Center-Middletown Regional Hospital | Franklin | Ohio | United States | 45005-1066 |
| 331 | Dayton Physicians LLC-Atrium | Franklin | Ohio | United States | 45005 |
| 332 | Central Ohio Breast and Endocrine Surgery | Gahanna | Ohio | United States | 43230 |
| 333 | Dayton Physicians LLC-Wayne | Greenville | Ohio | United States | 45331 |
| 334 | Wayne Hospital | Greenville | Ohio | United States | 45331 |
| 335 | Mount Carmel Grove City Hospital | Grove City | Ohio | United States | 43123 |
| 336 | Greater Dayton Cancer Center | Kettering | Ohio | United States | 45409 |
| 337 | Kettering Medical Center | Kettering | Ohio | United States | 45429 |
| 338 | Fairfield Medical Center | Lancaster | Ohio | United States | 43130 |
| 339 | Saint Rita's Medical Center | Lima | Ohio | United States | 45801 |
| 340 | OhioHealth Mansfield Hospital | Mansfield | Ohio | United States | 44903 |
| 341 | Marietta Memorial Hospital | Marietta | Ohio | United States | 45750 |
| 342 | OhioHealth Marion General Hospital | Marion | Ohio | United States | 43302 |
| 343 | UH Seidman Cancer Center at Landerbrook Health Center | Mayfield Heights | Ohio | United States | 44124 |
| 344 | Knox Community Hospital | Mount Vernon | Ohio | United States | 43050 |
| 345 | Licking Memorial Hospital | Newark | Ohio | United States | 43055 |
| 346 | Newark Radiation Oncology | Newark | Ohio | United States | 43055 |
| 347 | Mercy Health Perrysburg Cancer Center | Perrysburg | Ohio | United States | 43551 |
| 348 | Southern Ohio Medical Center | Portsmouth | Ohio | United States | 45662 |
| 349 | Springfield Regional Cancer Center | Springfield | Ohio | United States | 45504 |
| 350 | Springfield Regional Medical Center | Springfield | Ohio | United States | 45505 |
| 351 | Saint Vincent Mercy Medical Center | Toledo | Ohio | United States | 43608 |
| 352 | Mercy Health - Saint Anne Hospital | Toledo | Ohio | United States | 43623 |
| 353 | Toledo Clinic Cancer Centers-Toledo | Toledo | Ohio | United States | 43623 |
| 354 | Dayton Physicians LLC-Upper Valley | Troy | Ohio | United States | 45373 |
| 355 | Upper Valley Medical Center | Troy | Ohio | United States | 45373 |
| 356 | University Hospitals Sharon Health Center | Wadsworth | Ohio | United States | 44281 |
| 357 | Saint Joseph Warren Hospital | Warren | Ohio | United States | 44484 |
| 358 | University of Cincinnati Cancer Center-West Chester | West Chester | Ohio | United States | 45069 |
| 359 | Saint Ann's Hospital | Westerville | Ohio | United States | 43081 |
| 360 | UH Seidman Cancer Center at Saint John Medical Center | Westlake | Ohio | United States | 44145 |
| 361 | Saint Elizabeth Youngstown Hospital | Youngstown | Ohio | United States | 44501 |
| 362 | Genesis Healthcare System Cancer Care Center | Zanesville | Ohio | United States | 43701 |
| 363 | Mercy Hospital Oklahoma City | Oklahoma City | Oklahoma | United States | 73120 |
| 364 | Saint Alphonsus Medical Center-Baker City | Baker City | Oregon | United States | 97814 |
| 365 | Saint Charles Health System | Bend | Oregon | United States | 97701 |
| 366 | Clackamas Radiation Oncology Center | Clackamas | Oregon | United States | 97015 |
| 367 | Providence Cancer Institute Clackamas Clinic | Clackamas | Oregon | United States | 97015 |
| 368 | Bay Area Hospital | Coos Bay | Oregon | United States | 97420 |
| 369 | Providence Newberg Medical Center | Newberg | Oregon | United States | 97132 |
| 370 | Saint Alphonsus Medical Center-Ontario | Ontario | Oregon | United States | 97914 |
| 371 | Providence Portland Medical Center | Portland | Oregon | United States | 97213 |
| 372 | Providence Saint Vincent Medical Center | Portland | Oregon | United States | 97225 |
| 373 | Oregon Health and Science University | Portland | Oregon | United States | 97239 |
| 374 | Saint Charles Health System-Redmond | Redmond | Oregon | United States | 97756 |
| 375 | Lehigh Valley Hospital-Cedar Crest | Allentown | Pennsylvania | United States | 18103 |
| 376 | Lehigh Valley Hospital - Muhlenberg | Bethlehem | Pennsylvania | United States | 18017 |
| 377 | Christiana Care Health System-Concord Health Center | Chadds Ford | Pennsylvania | United States | 19317 |
| 378 | Pocono Medical Center | East Stroudsburg | Pennsylvania | United States | 18301 |
| 379 | Lehigh Valley Hospital-Hazleton | Hazleton | Pennsylvania | United States | 18201 |
| 380 | Reading Hospital | West Reading | Pennsylvania | United States | 19611 |
| 381 | Smilow Cancer Hospital Care Center - Westerly | Westerly | Rhode Island | United States | 02891 |
| 382 | Ralph H Johnson VA Medical Center | Charleston | South Carolina | United States | 29401 |
| 383 | Medical University of South Carolina | Charleston | South Carolina | United States | 29425 |
| 384 | Saint Francis Hospital | Greenville | South Carolina | United States | 29601 |
| 385 | Saint Francis Cancer Center | Greenville | South Carolina | United States | 29607 |
| 386 | Avera Cancer Institute | Sioux Falls | South Dakota | United States | 57105 |
| 387 | Saint Joseph Regional Cancer Center | Bryan | Texas | United States | 77802 |
| 388 | Huntsman Cancer Institute/University of Utah | Salt Lake City | Utah | United States | 84112 |
| 389 | University of Virginia Cancer Center | Charlottesville | Virginia | United States | 22908 |
| 390 | Centra Lynchburg Hematology-Oncology Clinic Inc | Lynchburg | Virginia | United States | 24501 |
| 391 | Virginia Cancer Institute | Richmond | Virginia | United States | 23230 |
| 392 | Virginia Commonwealth University/Massey Cancer Center | Richmond | Virginia | United States | 23298 |
| 393 | Providence Regional Cancer System-Aberdeen | Aberdeen | Washington | United States | 98520 |
| 394 | PeaceHealth Saint Joseph Medical Center | Bellingham | Washington | United States | 98225 |
| 395 | Harrison HealthPartners Hematology and Oncology-Bremerton | Bremerton | Washington | United States | 98310 |
| 396 | Harrison Medical Center | Bremerton | Washington | United States | 98310 |
| 397 | Highline Medical Center-Main Campus | Burien | Washington | United States | 98166 |
| 398 | Providence Regional Cancer System-Centralia | Centralia | Washington | United States | 98531 |
| 399 | Swedish Cancer Institute-Edmonds | Edmonds | Washington | United States | 98026 |
| 400 | Saint Elizabeth Hospital | Enumclaw | Washington | United States | 98022 |
| 401 | Providence Regional Cancer Partnership | Everett | Washington | United States | 98201 |
| 402 | Saint Francis Hospital | Federal Way | Washington | United States | 98003 |
| 403 | Swedish Cancer Institute-Issaquah | Issaquah | Washington | United States | 98029 |
| 404 | Kadlec Clinic Hematology and Oncology | Kennewick | Washington | United States | 99336 |
| 405 | Providence Regional Cancer System-Lacey | Lacey | Washington | United States | 98503 |
| 406 | Saint Clare Hospital | Lakewood | Washington | United States | 98499 |
| 407 | PeaceHealth Saint John Medical Center | Longview | Washington | United States | 98632 |
| 408 | Harrison HealthPartners Hematology and Oncology-Poulsbo | Poulsbo | Washington | United States | 98370 |
| 409 | Pacific Gynecology Specialists | Seattle | Washington | United States | 98104 |
| 410 | Swedish Medical Center-Ballard Campus | Seattle | Washington | United States | 98107 |
| 411 | Swedish Medical Center-First Hill | Seattle | Washington | United States | 98122-4307 |
| 412 | Swedish Medical Center-Cherry Hill | Seattle | Washington | United States | 98122-5711 |
| 413 | PeaceHealth United General Medical Center | Sedro-Woolley | Washington | United States | 98284 |
| 414 | Providence Regional Cancer System-Shelton | Shelton | Washington | United States | 98584 |
| 415 | Franciscan Research Center-Northwest Medical Plaza | Tacoma | Washington | United States | 98405 |
| 416 | Northwest Medical Specialties PLLC | Tacoma | Washington | United States | 98405 |
| 417 | PeaceHealth Southwest Medical Center | Vancouver | Washington | United States | 98664 |
| 418 | Providence Saint Mary Regional Cancer Center | Walla Walla | Washington | United States | 99362 |
| 419 | Providence Regional Cancer System-Yelm | Yelm | Washington | United States | 98597 |
| 420 | ThedaCare Regional Cancer Center | Appleton | Wisconsin | United States | 54911 |
| 421 | SSM Health Dean Medical Group - Baraboo | Baraboo | Wisconsin | United States | 53913 |
| 422 | Aurora Cancer Care-Southern Lakes VLCC | Burlington | Wisconsin | United States | 53105 |
| 423 | Marshfield Clinic-Chippewa Center | Chippewa Falls | Wisconsin | United States | 54729 |
| 424 | Aurora Saint Luke's South Shore | Cudahy | Wisconsin | United States | 53110 |
| 425 | Marshfield Medical Center-EC Cancer Center | Eau Claire | Wisconsin | United States | 54701 |
| 426 | Aurora Health Care Germantown Health Center | Germantown | Wisconsin | United States | 53022 |
| 427 | Aurora Cancer Care-Grafton | Grafton | Wisconsin | United States | 53024 |
| 428 | Aurora BayCare Medical Center | Green Bay | Wisconsin | United States | 54311 |
| 429 | Aurora Cancer Care-Kenosha South | Kenosha | Wisconsin | United States | 53142 |
| 430 | Gundersen Lutheran Medical Center | La Crosse | Wisconsin | United States | 54601 |
| 431 | Mayo Clinic Health System-Franciscan Healthcare | La Crosse | Wisconsin | United States | 54601 |
| 432 | Marshfield Clinic - Ladysmith Center | Ladysmith | Wisconsin | United States | 54848 |
| 433 | William S Middleton VA Medical Center | Madison | Wisconsin | United States | 53705 |
| 434 | Dean Hematology and Oncology Clinic | Madison | Wisconsin | United States | 53717 |
| 435 | University of Wisconsin Hospital and Clinics | Madison | Wisconsin | United States | 53792 |
| 436 | Aurora Bay Area Medical Group-Marinette | Marinette | Wisconsin | United States | 54143 |
| 437 | Marshfield Medical Center-Marshfield | Marshfield | Wisconsin | United States | 54449 |
| 438 | Aurora Cancer Care-Milwaukee | Milwaukee | Wisconsin | United States | 53209 |
| 439 | Aurora Saint Luke's Medical Center | Milwaukee | Wisconsin | United States | 53215 |
| 440 | Aurora Sinai Medical Center | Milwaukee | Wisconsin | United States | 53233 |
| 441 | Marshfield Clinic-Minocqua Center | Minocqua | Wisconsin | United States | 54548 |
| 442 | ProHealth D N Greenwald Center | Mukwonago | Wisconsin | United States | 53149 |
| 443 | Cancer Center of Western Wisconsin | New Richmond | Wisconsin | United States | 54017 |
| 444 | ProHealth Oconomowoc Memorial Hospital | Oconomowoc | Wisconsin | United States | 53066 |
| 445 | Vince Lombardi Cancer Clinic - Oshkosh | Oshkosh | Wisconsin | United States | 54904 |
| 446 | Aurora Cancer Care-Racine | Racine | Wisconsin | United States | 53406 |
| 447 | Marshfield Medical Center-Rice Lake | Rice Lake | Wisconsin | United States | 54868 |
| 448 | Vince Lombardi Cancer Clinic-Sheboygan | Sheboygan | Wisconsin | United States | 53081 |
| 449 | Marshfield Clinic Stevens Point Center | Stevens Point | Wisconsin | United States | 54482 |
| 450 | Aurora Medical Center in Summit | Summit | Wisconsin | United States | 53066 |
| 451 | Vince Lombardi Cancer Clinic-Two Rivers | Two Rivers | Wisconsin | United States | 54241 |
| 452 | ProHealth Waukesha Memorial Hospital | Waukesha | Wisconsin | United States | 53188 |
| 453 | UW Cancer Center at ProHealth Care | Waukesha | Wisconsin | United States | 53188 |
| 454 | Marshfield Clinic-Wausau Center | Wausau | Wisconsin | United States | 54401 |
| 455 | Aurora Cancer Care-Milwaukee West | Wauwatosa | Wisconsin | United States | 53226 |
| 456 | Aurora West Allis Medical Center | West Allis | Wisconsin | United States | 53227 |
| 457 | Marshfield Medical Center - Weston | Weston | Wisconsin | United States | 54476 |
| 458 | Marshfield Clinic - Wisconsin Rapids Center | Wisconsin Rapids | Wisconsin | United States | 54494 |
| 459 | Billings Clinic-Cody | Cody | Wyoming | United States | 82414 |
| 460 | Welch Cancer Center | Sheridan | Wyoming | United States | 82801 |
Sponsors and Collaborators
- ECOG-ACRIN Cancer Research Group
- National Cancer Institute (NCI)
Investigators
- Principal Investigator: Shaji K Kumar, ECOG-ACRIN Cancer Research Group
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- EAA181
- NCI-2020-06647
- EAA181
- EAA181
- U10CA180820